Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
|
|
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 10/04/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/04/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 08/17/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/05/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/30/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/30/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/30/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/30/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 10% stake in Reviva Pharmaceuticals Holdings, Inc. |
| 01/04/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/18/2022 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 10/18/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/11/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/06/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 09/19/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 09/12/2022 |
SC 13D/A
| VEDANTA PARTNERS, LLC reports a 19.9% stake in Reviva Pharmaceuticals Holdings, Inc. |
| 09/07/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: _______ Issue Date: September 8, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms use...",
"COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: _______ Initial Exercise Date: September 8, 2022 Issue Date: September 8, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 8, 2022 and on or prior to 5:00 p.m. on September 8, 2027 but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Defi...",
" ",
"SECURITIES PURCHASE AGREEMENT",
"SECURITIES PURCHASE AGREEMENT",
" ",
" " |
|
| 09/07/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/28/2022 |
8-K
| Quarterly results |
| 07/27/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
|
|
|